Letetresgene autoleucel

Phase 2Cell therapy

GSK

Letetresgene autoleucel is one of 87 small molecule programs targeting Liposarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LiposarcomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Multiple MyelomaActive, not recruiting

Synovial SarcomaActive, not recruiting

LiposarcomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

Synovial SarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

PORTRAZZA

Eli Lilly

Preclinical

8 2

Lenvima

Eisai

Preclinical

6 3

Letetresgene autoleucel

GSK

Phase 2

1 4

Imjudo

AstraZeneca

Preclinical

5 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Tyrosine Kinase Inhibitor

Pfizer

Preclinical

2 9

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—10

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Synovial Sarcoma1 trial

Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Active, not recruiting·UUSWM, LLC (dba US WorldMeds)·Phase 2·NCT05993299·7 enrolled

Multiple Myeloma1 trial

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Terminated· GSK logo

GSK·Phase 1·NCT03168438·6 enrolled

Non-Small Cell Lung Cancer1 trial

Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· GSK logo

GSK·Phase 1·NCT02588612·10 enrolled

Liposarcoma1 trial

Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma

Completed· GSK logo

GSK·Phase 2·NCT02992743·23 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Letetresgene autoleucel. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Letetresgene autoleucel compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Letetresgene autoleucel. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: GSK

Letetresgene autoleucel

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Synovial Sarcoma1 trial

Multiple Myeloma1 trial

Non-Small Cell Lung Cancer1 trial

Liposarcoma1 trial

References

Drug Info

Quick Facts

Related News